Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone adjunctive treatment for negative symptoms in schizophrenia
IRCT20091229002935N8Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Spironolactone add-on with Placebo add-on (2 arms). Primary endpoint: Severity of schizophrenia. Started Nov 2019; status: completed.
02
Drugs
spironolactone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20091229002935N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091229002935N8.